EVElise De Vos

Elise De Vos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elise De Vos has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Features and Outcomes Associated with a Clade IIb Mpox Virus Outbreak in Sierra Leone, Jan-Aug 2025

    by Darlinda F. Jiba, Elise De Vos, Eugene Bangwen, Agnes Dora Bangura, Sahr Foday, Joseph Baio Kamara, James Sylvester Squire, Mohamed Boie Jalloh, Daniel Sesay, Ibrahim Franklyn Kamara, et al.

    Background: Several lineages of mpox virus associated with sustained human-to-human transmission have recently caused major outbreaks worldwide. Following its emergence in Nigeria in 2017, Clade IIb caused a global outbreak in 2022 that primarily affected high-income countries and was characterised by low mortality and transmission within sexual networks of men who have sex with men. In January 2025, a large outbreak caused by Clade IIb mpox virus was declared in Sierra Leone. Here, we describe the clinical features and outcomes of individuals affected during this outbreak.Methods: We conducted a secondary analysis of routinely collected outbreak surveillance and clinical data from two mpox referral centers in Freetown, Sierra Leone. Individuals with PCR-confirmed mpox between Jan 10 and Aug 17, 2025 were included.Findings: Data were available for 1,084 individuals with confirmed mpox, 611 (56.4%) men and 472 (43.5%) women. Most cases were individuals aged 15–30 years (528/1084, 48.7%). HIV infection was present in 153 (14.1%) individuals, of whom 105 (68.6%) were newly diagnosed, and over half had CD4 counts ≤200 cells/μL. Genital lesions were reported in 904 (83.5%). Overall mortality was 3.0% (33/1084). Deaths were strongly concentrated among people living with HIV (29/153, 19.0%) compared with those without HIV (4/931, 0.4%) and occurred mainly in individuals with CD4 counts below ≤200 cells/μL. HIV infection was associated with substantially higher odds of mortality (causal odds ratio 47.96, 95% CI 18.93–155.76).Interpretation: During the 2025 outbreak in Sierra Leone, Clade IIb mpox appeared to spread predominantly through heterosexual contact and was associated with substantially higher mortality than reported during the 2022 global outbreak. Death occurred mainly among people living with HIV with advanced immunosuppression. Strengthening health systems, integrating mpox prevention and care with HIV services, and expanding targeted vaccination strategies are essential to reduce spreading and mortality in future outbreaks.

  • Open Access

    Prevalence, Characteristics and Evolution of Mpox-Related Ophthalmic Disease: A Prospective Cohort Study in South-Kivu, Democratic Republic of the Congo (MBOTE-EYE)

    by Theophile Kabesha, Christophe Van Dijck, Samuel Mudwanga, Sarah Houben, Yves Mujula, Papy Munganga, Jean-Claude Tshomba, Guy Mukari, Tony Wawina-Bokalanga, Eddy Kinganda-Lusamaki, et al.

    Background: Mpox-related ophthalmic disease (MPOXROD) ranges from mild conjunctivitis to sight-threatening keratitis, however, data based on systematic ophthalmological assessment are scarce. We aimed to characterise the prevalence, features, and temporal evolution of MPOXROD during a clade Ib mpox outbreak. Methods: We conducted MBOTE-EYE, a prospective ophthalmological sub-study, nested within a clinical characterisation cohort in Kamituga, South-Kivu, Democratic Republic of the Congo. All hospitalised patients with mpox confirmed by PCR in the prior 48 hours were eligible. Participants underwent comprehensive ophthalmological examination at enrolment, discharge, and days 29 and 59 post-diagnosis. Conjunctival swabs were collected for monkeypox virus PCR testing. MPOXROD was defined as conjunctivitis, scleritis, keratitis, uveitis, or optic nerve involvement. Risk factors were assessed using mixed-effects Poisson regression. Findings: Between 28 October 2024 and 30 June 2025, 310 participants were enrolled (median age 14 years, IQR 2.5-25.0; 53.5% female, n=166/310). At enrolment, conjunctivitis was present in 36.1% (95% CI 31.0–41.6%, n=112/310), keratitis in 7.7% (95% CI 5.3–11.3%), and anterior uveitis in 0.6% (95% CI 0.2–2.3%). Overall, 43.2% (95% CI 37.8–48.8%) developed MPOXROD during follow-up, most often bilaterally. Visual acuity <8/10 occurred in 22.9% (95% CI 17.6–29.2%, n=24/310), and persistent blindness in 0.9% (95% CI 0.24–5.5%, n=2/225), due to ulcerative keratitis. Periorbital lesions (adjusted risk ratio [aRR] 2.82, 95% CI 1.40–5.69) and severe malnutrition (aRR 5.06, 2.25–11.38) were independently associated with MPOXROD. Conjunctival swabs with PCR Ct values < 25 occurred exclusively in participants with active MPOXROD. Interpretation: Ophthalmic involvement in clade Ib mpox is common and frequently bilateral, with a substantial burden of keratitis and risk of vision loss, particularly in young children and severely malnourished individuals. These findings highlight the need for systematic eye examinations in mpox care and provide critical evidence to inform future trials of targeted ophthalmic therapies. Funding: None of the funders had a role in study design, analysis, interpretation, or writing.


  • Open Access

    Improving the efficiency of drug resistant tuberculosis treatment trials: a time-to-event alternative marker for bacteriological response and adaptive minimization for randomization

    by Elise De Vos, Annelies Van Rie, Steven Abrams

    Background: Establishing the efficacy of new treatments for rifampicin-resistant tuberculosis (RR-TB) is challenging due to the long-term clinical endpoints of two-year relapse-free survival. This study aimed to evaluate the effect of an alternative indicator of treatment response on sample size requirements and the use of a minimization strategy for randomization. Methods: Sample size estimates were compared when based on the commonly used endpoint of the proportion of patients achieving stable culture conversion (SCC) at 12 weeks versus a novel but corresponding indicator of treatment response based on a model of changes in mycobacterial load (MBL) over time. The non-linear mixed effects model, calibrated using data from a RR-TB cohort in the same setting, included a longitudinal MBL decline, a probabilistic component for mycobacteria presence in sputum, and a time-to-event model for culture positivity. Data were simulated for a prespecified treatment effect to compare the power of detecting the treatment effect for various sample sizes when using the commonly used endpoint and alternative indicator of treatment response. Additionally, the impact of random patient allocation versus a minimization strategy for randomization on covariate imbalance was assessed. Results: To achieve 80% power, 410 individuals were needed using the commonly used endpoint versus 110 participants when using the non-linear mixed effects model, corresponding to a 73% reduction in sample size. A small sample size results in high baseline covariate imbalance with random treatment group allocation, with a median relative imbalance of 0.104 for 110 participants versus 0.053 for 410 participants. This imbalance was reduced to 0.036 for 110 participants when an adaptive minimization procedure was implemented. Conclusion: Using a model of mycobacterial burden changes over time as an alternative indicator of treatment response, combined with a minimization procedure during the randomization process, significantly reduced the sample size which could, if validated, enhance the efficiency of RR-TB clinical trial design.


  • Open Access

    Epidemiological characteristics of mpox virus Clade Ib in the Democratic Republic of the Congo: the impact of transmission mode

    by Cécile Kremer, Sabin Sabiti Nundu, Emmanuel Hasivirwe Vakaniaki, Isabel Brosius, Guy Mukari, Papy Munganga, Eugene Bangwen, Jean Claude Tshomba, Yves Mujula, Elise De Vos, et al.

    Monkeypox virus (MPXV) Clade Ib, a new MPXV subclade associated with sustained human-to-human transmission, emerged in eastern DRC in late 2023. Early spread mainly occurred among the adult population, primarily through sexual contact. We investigated how key epidemiological characteristics of the new MPXV Clade Ib outbreak in the DRC differ by transmission mode. We estimated the mean serial interval to be 8.57 days (95% CI 7.15 – 9.91 days). The serial interval was approximately four days shorter for putative sexual compared to non-sexual transmission. We estimated the mean incubation period to be 9.56 days (95% CrI 8.22 – 11.02 days), and approximately two days shorter for putative sexual compared to non-sexual transmission. These observed differences in serial interval and incubation period estimates by transmission mode suggest that the context in which an outbreak occurs is an essential factor to consider when devising public health policies.


  • Open Access

    No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients

    by Eugene Bangwen, Nicole Berens‐Riha, Nicky de Vrij, Ann Ceulemans, Isabel Brosius, Elise De Vos, Thao‐Thy Pham, Emmanuel Bottieau, Johan van Griensven, Palmer Masumbe Netongo, et al.

    Previous studies indicated Clade I monkeypox virus infection to be associated with marked elevation of proinflammatory cytokines. This remains unexplored for Clade II‐associated disease, which has different clinical manifestations and prognosis. We used a 65‐plex cytokine, chemokine, and growth factor (CCG) panel to analyze serum samples of 100 male acute Clade IIb mpox patients and 26 healthy controls in Belgium. Cluster analyses revealed no strong or distinct CCG profiles distinguishing mpox patients from controls but suggested trends in certain cytokine modulation. Individual CCG analyses found elevated levels of cytokines (MIF, CD30, IL2R, IL18, APRIL, and TNFRII), chemokines (CCL4, CCL8, CCL22, CCL24, CXCL9, CXCL10, CXCL11, CXCL12, and CXCL13), and growth factors (HGF and VEGFA) in patients, while CCL11 and CXCL5 were significantly suppressed. We detected no differences in key proinflammatory cytokines, IL‐1α, IL‐1β, IL‐6, IL‐8 or anti‐inflammatory cytokines, IL‐4, IL‐10, IL‐13. In patients living with HIV, comparison with pre‐outbreak samples showed an increase in CXCL13 and a decrease in CXCL5, CCL2, CCL24, HGF, SCF, and TWEAK. The absence of discriminatory CCG profiles in Clade IIb mpox patients compared to healthy controls suggests there may be limited clinical applications of those markers.


  • Open Access

    Potential determinants of the decline in mpox cases in Belgium: A behavioral, epidemiological and seroprevalence study

    by Elise De Vos, Liesbeth Van Gestel, Isabel Brosius, Chris Kenyon, Bea Vuylsteke, Irith De Baetselier, Joachim Mariën, Eugene Bangwen, Simon Couvreur, Amaryl Lecompte, et al.


  • Open Access

    Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality

    by Elise De Vos, Daniel Westreich, Lesley Scott, Yara Voss de Lima, Wendy Stevens, Cindy Hayes, Pedro da Silva, Annelies Van Rie

    Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay was endorsed a decade ago for simultaneous diagnosis of tuberculosis and RR-TB, the impact of the assay on mortality among people with RR-TB has not yet been assessed. We analysed data of an observational prospective cohort study (EXIT-RIF) performed in South Africa. We applied a causal inference approach using inverse odds of sampling weights to rectify survivor bias and selection bias caused by differing screening guidelines. We also adjusted for confounding using a marginal structural model with inverse probability of treatment weights. We estimated the total effect of an RR-TB diagnosis made by the Xpert assay versus the pre-Xpert diagnostic algorithm (entailing a targeted Line Probe Assay (LPA) among TB-confirmed patients) on two-year mortality and we assessed mediation by RR-treatment initiation. Of the 749 patients diagnosed with RR-TB [247 (33%) by the pre-Xpert diagnostic algorithm and 502 (67%) by the Xpert assay], 42.7% died. Of these, 364 (48.6%) patients died in the pre-Xpert group and 200 (39.8%) in the Xpert group. People diagnosed with RR-TB by the Xpert assay had a higher odds of RR-TB treatment initiation compared to those diagnosed by the targeted LPA-based diagnostic process (OR 2.79; 95%CI 2.19–3.56). Receiving an RR-TB diagnosis by Xpert resulted in a 28% reduction in the odds of mortality within 2 years after presentation to the clinic (ORCI 0.72; 95%CI 0.53–0.99). Causal mediation analysis suggests that the higher rate of RR-TB treatment initiation in people diagnosed by the Xpert assay explains the effect of Xpert on 2-year mortality [natural indirect effect odds ratio 0.90 (95%CI 0.85–0.96). By using causal inference methods in combination with high quality observational data, we could demonstrate that the introduction of the Xpert assay caused a 28% reduction in 2-year odds of mortality of RR-TB. This finding highlights the need for advocacy for a worldwide roll-out of rapid molecular tests. Because the effect is mainly caused by increased RR-TB treatment initiation, health care systems should also ensure timely initiation of effective treatment upon an RR-TB diagnosis.


  • Open Access

    Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage

    by Emmanuel Rivière, Lennert Verboven, Anzaan Dippenaar, Sander Goossens, Elise De Vos, Elizabeth Streicher, Bart Cuypers, Kris Laukens, Fathia Ben-Rached, Timothy C. Rodwell, et al.

    Studies have shown that variants in bedaquiline-resistance genes can occur in isolates from bedaquiline-naive patients. We assessed the prevalence of variants in all bedaquiline-candidate-resistance genes in bedaquiline-naive patients, investigated the association between these variants and lineage, and the effect on phenotype.


  • Open Access

    Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa

    by Selien Oostvogels, Serej D. Ley, Tim H. Heupink, Anzaan Dippenaar, Elizabeth M. Streicher, Elise De Vos, Conor J. Meehan, Keertan Dheda, Rob Warren, Annelies Van Rie

    Extensively drug-resistant tuberculosis (XDR-TB), defined as resistance to at least isoniazid (INH), rifampicin (RIF), a fluoroquinolone (FQ) and a second-line injectable drug (SLID), is difficult to treat and poses a major threat to TB control. The transmission dynamics and distribution of XDR Mycobacterium tuberculosis (Mtb) strains have not been thoroughly investigated. Using whole genome sequencing data on 461 XDR-Mtb strains, we aimed to investigate the geographical distribution of XDR-Mtb strains in the Western Cape Province of South Africa over a 10 year period (2006–2017) and assess the association between Mtb sub-lineage, age, gender, geographical patient location and membership or size of XDR-TB clusters. First, we identified transmission clusters by excluding drug resistance-conferring mutations and using the 5 SNP cutoff, followed by merging clusters based on their most recent common ancestor. We then consecutively included variants conferring resistance to INH, RIF, ethambutol (EMB), pyrazinamide (PZA), SLIDs and FQs in the cluster definition. Cluster sizes were classified as small (2–4 isolates), medium (5–20 isolates), large (21–100 isolates) or very large (>100 isolates) to reflect the success of individual strains. We found that most XDR-TB strains were clustered and that including variants conferring resistance to INH, RIF, EMB, PZA and SLIDs in the cluster definition did not significantly reduce the proportion of clustered isolates (85.5–82.2 %) but increased the number of patients belonging to small clusters (4.3–12.4 %, P=0.56). Inclusion of FQ resistance-conferring variants had the greatest effect, with 11 clustered isolates reclassified as unique while the number of clusters increased from 17 to 37. Lineage 2 strains (lineage 2.2.1 typical Beijing or lineage 2.2.2 atypical Beijing) showed the large clusters which were spread across all health districts of the Western Cape Province. We identified a significant association between residence in the Cape Town metropole and cluster membership (P=0.016) but no association between gender, age and cluster membership or cluster size (P=0.39). Our data suggest that the XDR-TB epidemic in South Africa probably has its origin in the endemic spread of MDR Mtb and pre-XDR Mtb strains followed by acquisition of FQ resistance, with more limited transmission of XDR Mtb strains. This only became apparent with the inclusion of drug resistance-conferring variants in the definition of a cluster. In addition to the prevention of amplification of resistance, rapid diagnosis of MDR, pre-XDR and XDR-TB and timely initiation of appropriate treatment is needed to reduce transmission of difficult-to-treat TB.


  • Open Access

    The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis

    by Michael G Whitfield, Robin M Warren, Vanessa Mathys, Lesley Scott, Elise De Vos, Wendy Stevens, Elizabeth M Streicher, Guido Groenen, Frederick A Sirgel, Annelies Van Rie

    Use of the Xpert MTB/RIF assay has increased the number of people diagnosed with rifampicin-resistant tuberculosis (RR-TB), especially in South Africa where Xpert is now the initial diagnostic for individuals with TB symptoms. We hypothesized that a proportion of RR-TB patients determined by Xpert can be treated with a rifabutin-containing regimen. Rifabutin susceptibility by rpoB mutation was assessed in 349 individuals from South Africa and 172 from Belgium. rpoB polymorphisms were identified by Sanger sequencing. Rifampicin and rifabutin susceptibility was assessed phenotypically. A systematic review was performed to comprehensively collate information on rifabutin susceptibility by rpoB polymorphism. Rifabutin susceptibility was assigned to rpoB polymorphisms based on their positive likelihood ratios and ORs. One hundred and twelve rpoB polymorphisms (67.9% from literature) were identified from all 2045 RR-TB patients, of which 17 polymorphisms could be classified as susceptible/resistant to rifabutin. Eleven polymorphisms were associated with rifabutin susceptibility. The 516GTC mutation was the most common, representing 70% (South Africa) and 76% (Belgium) of all rifabutin-susceptible isolates. At a population level, the 11 polymorphisms associated with rifabutin susceptibility occurred in 33.2% and 16.6% of all South African and Belgian patients diagnosed with RR-TB, respectively. Identification of the exact rpoB polymorphism leading to the diagnosis of RR-TB has the potential to allow inclusion of rifabutin in the treatment regimen of a substantial proportion of RR-TB patients. A randomized controlled trial evaluating the efficacy of a rifabutin-containing TB treatment regimen in these selected patients is needed to provide the evidence required for a change in policy.